Hyderabad,25th April 2024 : The Telangana Drug Control Administration (DCA) has taken decisive action against the distribution of ‘DICLOJAN Forte’ tablets following the discovery of false claims on the product’s label. This move underscores the government’s commitment to ensuring the safety and accuracy of pharmaceutical products available to the public.
The seizure comes as a result of a thorough investigation conducted by the Telangana DCA, which revealed discrepancies between the claims made on the label of ‘DICLOJAN Forte’ tablets and the actual composition of the medication. Officials found that the label contained misleading information regarding the tablet’s potency and therapeutic effects, raising concerns about the potential risks posed to consumers.
DICLOJAN Forte, purported to be a pain relief medication, had been marketed with claims of enhanced efficacy and potency. However, upon closer scrutiny, it was found that these claims were not substantiated by scientific evidence and were therefore deemed false and misleading.
The Telangana DCA has taken swift action to prevent further distribution of the product and has initiated legal proceedings against the responsible parties for violating pharmaceutical regulations. This proactive stance underscores the importance of stringent oversight in the pharmaceutical industry to protect consumer health and safety.
In light of this incident, health authorities are urging consumers to remain vigilant when purchasing over-the-counter medications and to verify the authenticity of product claims. They emphasize the importance of consulting healthcare professionals for appropriate guidance and recommendations regarding the use of pharmaceutical products.
The seizure of ‘DICLOJAN Forte’ tablets serves as a reminder of the critical role played by regulatory agencies in upholding quality standards and ensuring transparency in the pharmaceutical sector. Through continued vigilance and enforcement efforts, authorities aim to safeguard public health and maintain trust in the integrity of medicinal products.
